Clinical Trial Update: A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia [Phase 1]

View source ↗

Summary

Phase Ib trial evaluating subcutaneous blinatumomab in combination with revumenib for KMT2A-rearranged acute lymphoblastic leukemia; the study is not yet recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Kmt2a-rearranged Acute Lymphoblastic Leukemia

Drugs mentioned

• Blinatumomab (blinatumomab)
• Revumenib (revumenib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Blinatumomab, Revumenib | Phase 1 | Status: NOT_YET_RECRUITING